Drospirenone/Ethinyl Estradiol Versus Rosiglitazone Treatment in Overweight Adolescents with Polycystic Ovary Syndrome: Comparison of Metabolic, Hormonal, and Cardiovascular Risk Factors

CONTEXT: Adolescents with polycystic ovary syndrome (PCOS) have insulin resistance and higher rates of the metabolic syndrome. OBJECTIVE: Our objective was to compare the effects of 6 months treatment with drospirenone/ethinyl estradiol (EE) (3 mg/30 μg) vs. rosiglitazone (4 mg) daily on the hormona...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Tfayli, Hala, Ulnach, Julia Warren, Lee, SoJung, Sutton-Tyrrell, Kim, Arslanian, Silva
Formato: Artigo
Lenguaje:Inglês
Publicado: Endocrine Society 2011
Materias:
Endocrine Care
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3203622/
https://ncbi.nlm.nih.gov/pubmed/21325466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2010-2547
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares